Michael-Robin Witt

Title: Michael-Robin Witt: Innovator in Genistein Research

Introduction

Michael-Robin Witt is a notable inventor based in Södertälje, Sweden. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of novel crystalline forms of genistein. With a total of three patents to his name, Witt's work has the potential to impact cancer treatment methodologies.

Latest Patents

Witt's latest patents focus on new crystalline forms of genistein. These include crystalline genistein sodium salt dihydrate, crystalline genistein potassium salt dihydrate, crystalline genistein calcium salt, crystalline genistein magnesium salt, crystalline genistein L-lysine salt, crystalline genistein N-methylglucamine salt, crystalline genistein N-ethylglucamine salt, crystalline genistein diethylamine salt, and crystalline genistein monohydrate. The patents also describe therapeutic compositions that contain at least one of these crystalline forms of genistein and/or a genistein salt, along with a pharmaceutically acceptable carrier. Furthermore, the disclosures relate to methods of treating cancer by administering a therapeutically effective amount of these compositions to patients in need.

Career Highlights

Throughout his career, Michael-Robin Witt has worked with Axcentua Pharmaceuticals AB, where he has contributed to innovative research and development projects. His expertise in pharmaceutical sciences has positioned him as a key figure in the exploration of genistein's therapeutic potential.

Collaborations

Witt has collaborated with notable colleagues such as Anders Berkenstam and Stefan Rehnmark. Their combined efforts have further advanced the research and application of genistein in medical treatments.

Conclusion

Michael-Robin Witt's innovative work in the field of genistein research exemplifies the impact of dedicated inventors in advancing medical science. His contributions hold promise for future therapeutic applications in cancer treatment.